Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
LDB1-dependent enhancer connectivity defines T-cell leukemia identities and masks metabolic vulnerabilities.
Journal: bioRxiv : the preprint server for biology
Published: July 10, 2026
Humanized immune system animal models and their recent applications.
Journal: Animal models and experimental medicine
Published: December 08, 2025
Pitavastatin counteracts venetoclax resistance mechanisms in acute myeloid leukemia by depleting geranylgeranyl pyrophosphate.
Journal: bioRxiv : the preprint server for biology
Published: November 24, 2025
TP53-agnostic lethality through combined pan-HDAC and CDK inhibition in acute myeloid leukemia.
Journal: Cancer letters
Published: January 31, 2025
Upfront menin-inhibitor resistance in multiply pretreated leukemias.
Journal: Experimental hematology
Published: January 26, 2025
NAMPT haploinsufficiency is a collateral lethal therapeutic vulnerability in high-risk myeloid malignancies with TP53 inactivation.
Journal: Blood neoplasia
Published: December 06, 2024
Chemoresistance of TP53 mutant acute myeloid leukemia requires the mevalonate byproduct, geranylgeranyl pyrophosphate, for induction of an adaptive stress response.
Journal: Leukemia
Published: December 05, 2024
A line in shifting sand: Can we define and target TP53 mutated MDS?
Journal: Seminars in hematology
Published: August 05, 2024
TP53 mutations and TET2 deficiency cooperate to drive leukemogenesis and establish an immunosuppressive environment.
Journal: The Journal of clinical investigation
Published: June 20, 2024
Immunohistochemistry-based detection of TP53 mutations in acute myeloid leukemia: a promising high sensitivity diagnostic approach.
Journal: Leukemia & lymphoma
Published: March 27, 2024
Last Updated: 09/26/2026